Axxess Pharma, Inc. Retains A-Z Pharma for Strategic Consultancy Services to Accelerate International Expansion of Product Sales and Portofilo

MARKHAM, ON--(Marketwire - November 17, 2010) - Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce A-Z Pharma, Inc. has been retained by the company under a comprehensive consultancy agreement.

In this context, Axxess Pharma will be working closely with Ms. Rahma Mbarki, Vice President of Marketing and Sales at A-Z Pharma. Ms. Mbarki has over 18 years of professional experience, of which 10 years is in the pharmaceutical industry. Ms. Mbarki’s experience includes drug development, regulatory affairs, process control, contract preparation, negotiation and management, private financing for R&D, and introduction of new products to North America, Latin America, South East Asia, Middle East and North Africa for substantial year over year residual sales growth.

A-Z Pharma’s primary responsibilities for Axxess Pharma will be:

1. Sourcing and securing in-licensing product opportunities;
2. Seeking product portfolio expansion and out-licensing;
3. Finding potential customers for the products of Axxess Pharma in the Territory;
4. Providing assistance in price negotiations with customers;
5. Conducting business review and monitor progress with selected partners;
6. Follow up on logistics;
7. Assist in the registration processes with Health Canada for the products sourced by A-Z Pharma;
8. Assist with marketing activities (help getting promotional materials and selling aids from the suppliers found by A-Z Pharma).

“We are pleased to engage and integrate A-Z Pharma’s proven services into the exciting things we are looking to accomplish with our company. Their extensive international experience and support will be instrumental, from product development to international product distribution and sales. We have a large product line which is set to hit the market in the coming months. A-Z Pharma will be working closely with our company to ensure strong long-term global sales,” stated Gerald Sequeira, President.

For more information, please contact Investor Relations at (973) 351-3868.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology,Neurology and Urology.

Safe Harbor

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.